Moreover, Xie et al. (2021) concluded that IGF2BP3 was involved in the metabolism of IGF2BP3/CDKN2B-AS1/NUF2 axis, this genetic mechanism suggests that IGF2BP3 may be an ideal tumor marker and therapeutic target for ccRCC in the future. This evidence concerns the gene CDKN2B and nonpapillary renal cell carcinoma.